IE
ENGN icon

Israel Englander’s enGene Therapeutics ENGN Stock Holding History

Israel Englander’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67M Buy
966,627
+6,946
+0.7% +$28.3K ﹤0.01% 3957
2026
Q1 		$6.54M Sell
959,681
-539,839
-36% -$4.81M ﹤0.01% 2629
2025
Q4 		$13.5M Buy
1,499,520
+1,479,018
+7,214% +$11.9M 0.01% 1949
2025
Q3 		$140K Buy
20,502
+7,472
+57% +$34.1K ﹤0.01% 5636
2025
Q2 		$47.4K Buy
+13,030
New +$48.9K ﹤0.01% 5623

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Israel Englander's ENGN Position: Q2 2026 in Review

Israel Englander increased its enGene Therapeutics (ENGN) stake by 0.72% in Q2 2026, buying an estimated $28.3K and bringing the position to 966,627 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #3957.

Israel Englander first reported a position in ENGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $13.5M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Israel Englander held 966,627 shares of enGene Therapeutics worth $1.67M as of Q2 2026.
  • Israel Englander bought 6,946 enGene Therapeutics shares in Q2 2026, an estimated $28.3K.
  • enGene Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3957 holding.
  • Israel Englander first reported a position in enGene Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Israel Englander's enGene Therapeutics position peaked at $13.5M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.